Effect of Statins on Platelet PAR-1 Thrombin Receptor in Patients With the Metabolic Syndrome (From the PAR-1 Inhibition by Statins [PARIS] Study)

American Journal of Cardiology

Volumn 97, Issue 9, 2006, Pages 1332-1336

  Serebruany, Victor L ^a   Miller, Michael ^b   Pokov, Alex N ^a   Malinin, Alex I ^a   Lowry, David R ^c   Tanguay, Jean Francois ^d   Hennekens, Charles H ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c Midatlantic Cardiovascular Associates   (United States)

^d MONTREAL HEART INSTITUTE   (Canada)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EPITOPE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; PROTEINASE ACTIVATED RECEPTOR 1; ROSUVASTATIN; SIMVASTATIN; THROMBIN RECEPTOR;

ADULT; ANTIGEN EXPRESSION; ARTICLE; COHORT ANALYSIS; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PLEIOTROPY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE FUNCTION; THROMBOSIS;

BLOOD PLATELETS; FEMALE; FLOW CYTOMETRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR, PAR-1;

EID: 33646065014     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.11.058     Document Type: Article

References (30)

1. Hebert P.R., Gaziano J.M., Chan K.S., and Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. an overview of randomized trials. JAMA 278 (1997) 313-321
2. Serruys P.W., de Feyter P., Macaya C., Kokott N., Puel J., Vrolix M., Branzi A., Bertolami M.C., Jackson G., Strauss B., Meier B., and Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. a randomized controlled trial. JAMA 287 (2002) 3215-3222
3. Futterman L.G., and Lemberg L. Statin pleiotropy. fact or fiction?. Am J Crit Care 13 (2004) 244-249
4. Halcox J.P., and Deanfield J.E. Beyond the laboratory. clinical implications for statin pleiotropy. Circulation 109 suppl 1 (2004) II42-II48
5. Schafer K., Kaiser K., and Konstantinides S. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. Thromb Haemost 93 (2005) 142-152
6. Undas A., Brozek J., and Musial J. Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease. Clin Lab 48 (2002) 287-296
7. Serebruany V.L., Midei M.G., Malinin A.I., Oshrine B.R., Lowry D.R., Sane D.C., Tanguay J.F., Steinhubl S.R., Berger P.B., O'Connor C.M., and Hennekens C.H. Absence of interaction between atorvastatin or other statins and clopidogrel. results from the INTERACTION study. Arch Intern Med 164 (2004) 2051-2057
8. Cupit L.D., Schmidt V.A., and Bahou W.F. Proteolitically activated receptor-3. a member of an emerging gene family of protease receptors expressed on vascular endothelial cells and platelets. Trends Cardiovasc Med 9 (1999) 42-48
9. Vu T.K., Hung D.T., Wheaton V.I., and Coughlin S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64 (1991) 1057-1068
10. Kahn M.L., Nakanishi-Matsui M., Shapiro M.J., Ishihara H., and Coughlin S.R. Protease activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103 (1999) 879-887
11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). final report. Circulation 106 (2002) 3143-3421
12. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., Smith Jr. S.C., Lenfant C., American Heart Association and National Heart, Lung, and and Blood Institute. Definition of metabolic syndrome. report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
13. Ault K.A. Flow cytometric measurement of platelet function and reticulated platelets. Ann NY Acad Sci 677 (1993) 293-308
14. Lias J.K. Clinical implications for statin pleiotropy. Curr Opin Lipidol 16 (2005) 624-629
15. Epstein M., and Campese V.M. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on renal function. Am J Kidney Dis 45 (2005) 2-14
16. McCarey D.W., Sattar N., and McInnes I.B. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?. Arthritis Res Ther 7 (2005) 55-61
17. Sotiriou C.G., and Cheng J.W. Beneficial effects of statins in coronary artery disease-beyond lowering cholesterol. Ann Pharmacother 34 (2000) 1432-1439
18. De Cristofaro R., and De Candia E. Thrombin domains. structure, function and interaction with platelet receptors. J Thromb Thrombolysis 15 (2003) 151-163
19. Patterson C., Stouffer G.A., Madamanchi N., and Runge M.S. New tricks for old dogs. nonthrombotic effects of thrombin in vessel wall biology. Circ Res 88 (2001) 987-997
20. Cupit L.D., Schmidt V.A., and Bahou W.F. Proteolytically activated receptor-3. a member of an emerging gene family of protease receptors expressed on vascular endothelial cells and platelets. Trends CardioVasc Med 9 (1999) 42-48
21. Phillips D.R. Thrombin interaction with human platelets. potentiation of thrombin-induced aggregation and release by inactivated thrombin. Thromb Diath Haemorrh 32 (1974) 207-215
22. Henriksen R.A., Samokhin G.P., and Tracy P.B. Thrombin-induced thromboxane synthesis by human platelets. properties of anion binding exosite I-independent receptor. Arterioscler Thromb Vasc Biol 17 (1997) 3519-3526
23. Weksler B.B., Ley C.W., and Jaffe E.A. Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A23187. J Clin Invest 62 (1978) 923-930
24. Sugama Y., Tiruppathi C., Offakidevi K., Andersen T.T., Fenton II J.W., and Malik A.B. Thrombin-induced expression of endothelial P-selectin and intercellular adhesion molecule-1. a mechanism for stabilizing neutrophil adhesion. J Cell Biol 119 (1992) 935-944
25. Major C.D., Santulli R.J., Derian C.K., and Andrade-Gordon P. Extracellular mediators in atherosclerosis and thrombosis. lessons from thrombin receptor knockout mice. Arterioscler Thromb Vasc Biol 23 (2003) 931-939
26. Flynn A.N., and Buret A.G. Proteinase-activated receptor 1 (PAR-1) and cell apoptosis. Apoptosis 9 (2004) 729-737
27. Sabri A., Guo J., Elouardighi H., Darrow A.L., Andrade-Gordon P., and Steinberg S.F. Mechanisms of protease-activated receptor-4 actions in cardiomyocytes. role of Src tyrosine kinase. J Biol Chem 278 (2003) 11714-11720
28. Mandal S.K., Rao L.V., Tran T.T., and Pendurthi U.R. A novel mechanism of plasmin-induced mitogenesis in fibroblasts. J Thromb Haemost 3 (2005) 163-169
29. Fenton II J.W., Jeske W.P., Catalfamo J.L., Brezniak D.V., Moon D.G., and Shen G.X. Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. Biochemistry (Mosc) 67 (2002) 85-91
30. Puccetti L., Bruni F., Bova G., Cercignani M., Palazzuoli A., Console E., Auteri A., and Pasqui A.L. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects. Nutr Metab Cardiovasc Dis 11 (2001) 378-387